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Endoglin is an integral membrane glycoprotein primarily
expressed in the vascular endothelium, but also found on
macrophages and stromal cells. It binds several members
of the transforming growth factor (TGF)-b family of
growth factors and modulates TGF-b1-dependent cellular
responses. However, it lacks cytoplasmic signaling motifs
and is considered as an auxiliary receptor for TGF-b. We
show here that endoglin is expressed in mouse and human
epidermis and in skin appendages, such as hair follicles
and sweat glands, as determined by immunohistochem-
istry. In normal interfollicular epidermis, endoglin was
restricted to basal keratinocytes and absent in differen-
tiating cells of suprabasal layers. Follicular expression of
endoglin was high in hair bulb keratinocytes, but
decreased in parts distal from the bulb. To address the
role of endoglin in skin carcinogenesis in vivo, Endoglin
heterozygous mice were subjected to long-term chemical
carcinogenesis treatment. Reduction in endoglin had a
dual effect during multistage carcinogenesis, by inhibiting
the early appearance of benign papillomas, but increasing
malignant progression to highly undifferentiated carcino-
mas. Our results are strikingly similar to those previously
reported for transgenic mice overexpressing TGF-b1 in the
epidermis. These data suggest that endoglin might
attenuate TGF-b1 signaling in normal epidermis and
interfere with progression of skin carcinogenesis.
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Introduction
The transforming growth factor-b (TGF-b) plays an
important role in epithelial homeostasis, as it modulates
the cellular phenotype and is a powerful inhibitor of cell
growth (Derynck et al., 2001; Piek and Roberts, 2001).
Members of the TGF-b superfamily exert their biologi-
cal effects by binding to a heteromeric complex contain-
ing two different transmembrane serine/threonine
kinases known as type I and type II signaling receptors
(Letterio and Roberts, 1998; Massague´, 1998). The
TGF-b receptor complex also contains two auxiliary
receptors named endoglin and betaglycan (Massague´,
1998). These are transmembrane proteins with large
extracellular domains and serine/threonine-rich cyto-
plasmic regions without consensus signaling motifs.
Endoglin binds TGF-b1, TGF-b3, activin-A, BMP-2,
and BMP-7 in the presence of the signaling receptors
types I and II (Cheifetz et al., 1992; Bello´n et al., 1993;
Letamendia et al., 1998a; Barbara et al., 1999), and
modulates TGF-b-dependent cellular responses (Lastres
et al., 1996; Letamendia et al., 1998a; Li et al., 2000;
Diez-Marques et al., 2002). Endoglin plays an important
role in mammalian physiology as demonstrated by
genetic inactivation, since Endoglin null (Eng/) murine
embryos die of vascular defects at 10–10.5 days post
coitum (Bourdeau et al., 1999; Li et al., 1999; Arthur
et al., 2000). Endoglin is a disulﬁde-linked homodimer
of 180 kDa expressed in endothelial cells (Gougos and
Letarte, 1988, 1990; Li et al., 2000), macrophages
(Lastres et al., 1992), stromal cells (St-Jacques et al.,
1994; Robledo et al., 1996), and other cellular lineages
within the vascular system and connective tissues
(Fonsatti et al., 2001). Several tumor cells also express
endoglin, including pre-B-cell and monocytic leukemia
(Quackenbush and Letarte, 1985; Haruta and Seon,
1986; Lastres et al., 1992; Zhang et al., 1996), melanoma
(Altomonte et al., 1996), choriocarcinoma (Letamendia
et al., 1998b), and ovarian carcinoma (Jindal et al.,
1995). However, little is known about the possible
expression and function of endoglin in epithelial cells.
Approximately 90% of all human tumors are of
epithelial origin. TGF-b has both positive and negative
effects on carcinogenesis. It behaves as a tumor
suppressor, early in tumorigenesis, but can also drive
malignant progression, invasion, and metastasis (seeReceived 7 February 2003; revised 30 May 2003; accepted 2 June 2003
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Akhurst and Balmain, 1999; Massague´ et al., 2000;
Derynck et al., 2001, for reviews). In spite of the large
number of studies addressing the role of TGF-b in
epithelial carcinogenesis, the speciﬁc role played by the
TGF-b coreceptor endoglin has not been evaluated in
vivo.
The mouse skin model of multistage carcinogenesis
has been widely studied and is well characterized
with respect to phenotypic and genetic changes
(Yuspa, 1994; Akhurst and Balmain, 1999). Tumor
initiation is induced by a single topical application
of the carcinogen 7,12-dimethylbenz(a)anthracene
(DMBA), and involves a speciﬁc oncogenic mutation
in the H-Ras gene (Quintanilla et al., 1986). Thereafter,
repeated application of the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA) results in the
outgrowth of highly differentiated benign papillomas.
A small subset of papillomas eventually progresses
to malignant squamous cell carcinomas, some of
which undergo an epithelial–mesenchymal transition to
spindle cell carcinomas (Klein-Szanto et al., 1989;
Buchmann et al., 1991). The spindle cell, the most
invasive and motile carcinoma cell type has altered the
expression of keratinocyte-speciﬁc markers, such as
cytokeratins, and show loss of E-cadherin expression
(Navarro et al., 1991; Dı´az-Guerra et al., 1992; Frontelo
et al., 1998).
Here, we describe the presence of endoglin in
keratinocytes of basal epidermis and hair follicles, the
two major cell compartments for tumor initiation in skin
carcinogenesis (Akhurst and Balmain, 1999; Taylor
et al., 2000). To investigate the role of endoglin in
carcinogenesis, Endoglin heterozygous (Engþ /) mice
were subjected to long-term chemical carcinogenesis
treatment with DMBA and TPA. We found that
endoglin haploinsufﬁciency had a dual effect during
multistage skin carcinogenesis, inhibiting the early
appearance of benign tumors, but increasing the late
malignant phenotype.
Results
Endoglin is expressed in keratinocytes of normal skin and
cutaneous lesions
The presence of endoglin was analysed in human normal
skin sections by immunohistochemistry using the
speciﬁc monoclonal antibody (mAb) SN6h. Endoglin
was expressed in the epidermis, restricted exclusively to
basal keratinocytes (Figure 1a, b). The immunostaining
pattern was discontinuous in the basal layer with some
cells staining weakly or not at all, and in patches in
certain regions of the plasma membrane and/or cyto-
Figure 1 Immunohistochemical detection of endoglin in human skin and skin appendages. (a, b) Interfollicular skin. Endoglin is
expressed in basal keratinocytes of the epidermis (e) and in dermal (d) blood vessels (inset in panel b). (c) Hair follicles. Note staining in
keratinocytes of the hair bulb (hb) and outer (ors) and inner (irs) root sheaths. No staining is found in the dermal papilla (dp) and in
parts distal from the hair bulb. The inset in this panel shows a higher magniﬁcation of the hair bulb. (d) Sweat glands showing positive
staining in basal and ductal cells. Original magniﬁcations:  100 (c),  400 (a, b, d, insets in b and c)
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plasm. This is in contrast to the continuous and cell-
surface pattern of endoglin expression seen in endothe-
lial cells of dermal blood vessels (Figure 1b, inset), used
as a positive control. The antibody did not stain
suprabasal keratinocytes and dermal ﬁbroblastic cells.
Endoglin was also present in keratinocytes of hair
follicles (Figure 1c). Intense staining was observed in the
hair matrix and in the proximal regions of the outer and
inner root sheaths, and decreased in parts distal from
the bulb. Mesenchyme-derived dermal papilla ﬁbro-
blasts were endoglin negative. As seen for interfollicular
epidermal cells, hair follicle keratinocytes expressed
endoglin in a polarized fashion, with the protein located
in certain regions of the plasma membrane and/or
cytoplasm in the form of granules or aggregates
(Figure 1c, inset). Basal and ductal cells of the sweat
gland were found to express endoglin strongly
(Figure 1d), while high nonspeciﬁc staining background
was observed in cells of the sebaceous gland (not
shown). Immunostaining of normal mouse skin sections
with the rat mAb MJ7/18 speciﬁc for murine endoglin
revealed the same pattern of protein expression in
follicular and interfollicular epidermis as in human skin
(see below in Figure 6).
Since endoglin was present in cells of the epidermis
and skin appendages, we analysed its expression in
several human cutaneous disorders. To this aim,
sections of verruca vulgaris (n¼ 3), seborrheic keratosis
(n¼ 3), nodular basal cell carcinomas (n¼ 7), and
squamous cell carcinomas (n¼ 10) were stained with
the mAb SN6h. A pattern of staining similar to that of
normal epidermis was found in all cases of verruca
vulgaris (not shown). In seborrheic keratosis, endoglin
staining was extended to proliferating keratinocytes
above the basal layer, while absent from terminally
differentiating keratinocytes (Figure 2a). All specimens
of nodular basal cell carcinomas were stained with the
speciﬁc mAb, revealing that endoglin was expressed
mainly at the periphery of tumor nests, as dots, on the
cell surface in contact with the basement membrane
zone. Reduced staining in the inner cell layers was seen
in all cases (Figure 2b). Immunohistochemical analysis
of squamous cell carcinomas showed that all tumors
expressed endoglin at variable levels regardless of the
differentation grade (Figure 2c, d). Positive staining was
observed in the periphery of tumor nests, but not in the
central keratinized areas of well-differentiated tumors
from which endoglin was excluded (Figure 2c).
Endoglin expression in murine keratinocyte cell lines
To characterize endoglin expression in cultured kerati-
nocytes at the mRNA and protein levels, we used a
panel of premalignant and malignant mouse epidermal
cell lines: PB (papilloma-derived cells), Pam212, HaCa4,
and PDV (squamous carcinoma cell lines), and the
spindle carcinoma cell lines Car C and Car B. Northern
blot experiments with a cDNA probe corresponding to
the extracellular domain of the molecule (see Materials
and methods) revealed a transcript of 3.1 kb in all the
cell lines (Figure 3a), but detection required a long
exposure of the autoradiography indicating a low level
Figure 2 Immunohistochemical detection of endoglin in human cutaneous disorders. (a) Seborrheic keratosis; e, epidermis; d, dermis.
(b) Nodular basal cell carcinoma showing polarized positive staining at the periphery of tumor nests in contact with the basement
membrane (bm). (c) Well-differentiated squamous cell carcinoma. Note positive staining in the periphery of the tumor while endoglin is
absent from the keratinized regions (k); s, stroma. (d) Poorly differentiated squamous cell carcinoma showing endoglin staining in
tumor cells. Original magniﬁcations:  100 (a),  200 (d),  400 (b, c)
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of endoglin mRNA expression in cultured keratinocytes.
This transcript has already been described in other
murine tissues such as the ovary, thymus, placenta, and
kidney (Ge and Butcher, 1994; St-Jacques et al., 1994;
Rodriguez-Pen˜a et al., 2002). The relative abundance of
the endoglin mRNAs among the cell lines was roughly
similar, except for PDV carcinoma cells that showed
lower levels in this experiment. The presence of endoglin
transcripts was conﬁrmed by RT–PCR (Figure 3b).
Using speciﬁc primers to mouse endoglin, a single 1040-
bp PCR product of the predicted size was obtained in all
the cell lines tested, including NIH3T3 ﬁbroblasts used
as a control. To conﬁrm that this band represented
endoglin, it was puriﬁed and sequenced, demonstrating
its identity with the published murine sequence (Ge and
Butcher, 1994; St-Jacques et al., 1994). Western blots
(under reducing conditions) clearly detected a polypep-
tide of about 95 kDa in PB, HaCa4, and PDV
keratinocytes (Figure 3c). A weaker band was present
in Pam212, whereas no speciﬁc signal could be detected
in Car C and Car B cell lines. Overall, the intensities of
the bands detected in the keratinocyte cell lines were
low, although comparable to that of NIH3T3 ﬁbro-
blasts. Parallel blots challenged with preimmune rat
IgG, as a negative control, conﬁrmed the speciﬁcity of
the mAb MJ7/18 (data not shown).
Reduced incidence of chemically induced benign
papillomas and enhanced progression to malignant
carcinomas in Endoglin heterozygous mice
To analyse the role of endoglin in carcinogenesis, we
took advantage of the Engþ / mouse that expresses a
single endoglin allele on a 129/Ola and C57Bl/6 mixed
background (backcrossed onto the C57Bl/6 background
for four generations, see Bourdeau et al., 1999). Two
independent skin carcinogenesis experiments were per-
formed using groups of seven (experiment 1) and eight
to 10 (experiment 2) male and female mice. Engþ / mice
and the homozygous littermates (Engþ /þ) were treated
with an initial dose of DMBA followed twice weekly
with TPA for about 20 weeks, as described in Materials
and methods. A signiﬁcant reduction in the number of
tumors per mouse and the total yield of tumors was
observed in the Engþ / versus Engþ /þ mice throughout
the observation period (Figure 4). The ﬁrst appearance
of papillomas was noticed on weeks 12 (experiment 1) or
8 (experiment 2) in Engþ /þ mice and 1–2 weeks later in
the corresponding Engþ / mice. Tumor induction
occurred in 87% of Engþ /þ mice and 44% of Engþ /
mice. No signiﬁcant differences in tumor development
were observed between males and females.
The histopathological examination of the tumors at
the end of the experiments (25 and 23 weeks post-
DMBA initiation in experiments 1 and 2, respectively)
revealed that all tumors in the Engþ /þ mice were benign
papillomas. However, in the Engþ / mice, despite a
threefold reduction in the total number of tumors versus
the controls, more than half of the developed tumors
were malignant carcinomas (Table 1). Papillomas in the
Engþ / and Engþ /þ mice were histologically very similar
with abundant keratin and a high level of differentiation
(Figure 5a). Engþ / carcinomas showed a variable
pattern of differentiation ranging from well-differen-
tiated squamous carcinomas grades I–II (Figure 5b) to
highly undifferentiated carcinomas grades III–IV that
showed very little evidence of cellular organization,
differentiation, or keratin production (Figure 5d, see
also Table 1). Carcinomas in the Engþ / mice were, in
general, very invasive and inﬁltration into the muscle
Figure 3 Analysis of endoglin expression in mouse epidermal cell
lines. (a) Northern blot hybridization reveals a transcript of 3.1-kb
expressed in all cell lines. A GAPDH probe was used as control for
RNA quality and amount. Times of exposure of the autoradio-
graphies were about 3 days for GAPDH and 20 days for endoglin
mRNA. (b) Detection of endoglin transcripts by PCR ampliﬁca-
tion. Samples of total RNA from the indicated cell lines were
incubated with the reverse transcriptase and the generated cDNAs
were used for PCR ampliﬁcation in the presence of speciﬁc primers.
A single 1040-bp band of the predicted size was detected in all the
cell lines. (c) Western blot analysis with the mAb MJ7/18 speciﬁc
for murine endoglin. The arrow indicates the position of the
speciﬁc band detected in keratinocyte and NIH3T3 cell lines. In the
bottom panel, the ﬁlter was reblotted with an anti-a-tubulin mAb
as a control for protein loading
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layer was often observed (Figure 5c). No obvious
differences in the inﬂammatory response were observed
between Engþ / and Engþ /þ tumors.
Endoglin expression was vastly increased in Engþ /þ
papillomas relative to normal skin, as shown by
immunohistochemistry. Strong immunoreactivity
was observed in basal and suprabasal keratinocytes
(Figure 6c), but not in differentiating keratinocytes of
the upper epidermal layers. Staining was mainly
located at the plasma membrane, although some
cells also showed an intense intracellular staining.
Endoglin expression in suprabasal keratinocytes
was preserved in hyperplastic epidermis adjacent
to the tumors (not shown). However, in skin
distant from the lesions, staining shifted to a pattern
similar to that found in the normal epidermis
(Figure 6a), endoglin being restricted to basal-like
cells and preferentially intracellular (Figure 6b).
Tumors induced in Engþ / mice showed poor immunor-
eactivity with mAb MJ7/18, although a weak plasma
membrane and cytoplasmic staining could be observed
in basal and suprabasal keratinocytes of papillomas
(Figure 6d).
These results show that a reduction of endoglin gene
dosage inhibits the formation of benign skin tumors, but
highly increases the frequency of malignant conversion.
Discussion
So far, most of the research studies on endoglin have
focused on its role in angiogenesis and vascular
remodeling. This is due to the fact that endoglin is
preferentially and strongly expressed in endothelial cells
(Gougos and Letarte, 1988; Li et al., 2000). Further-
more, mutations in the endoglin gene lead to haploin-
sufﬁciency and are responsible for the hereditary
hemorrhagic telangiectasia type 1 (HHT1), an auto-
somal dominant disorder characterized by multisystemic
vascular dysplasia, and recurrent hemorrhage (Guttma-
cher et al., 1995; Shovlin and Letarte, 1999; Marchuk
and Lux, 2001). In addition, endoglin expression is
regulated during heart development in human and
chicken (Qu et al., 1998; Vincent et al., 1998); and
endoglin-null mice obtained by targeted disruption of
the endoglin gene die at 10–10.5 days post coitum due to
vascular and cardiac abnormalities (Bourdeau et al.,
1999; Li et al., 1999; Arthur et al., 2000).
Aside from the endothelial expression of endoglin,
several laboratories have reported the presence of
endoglin in other cell types, mostly on cellular lineages
within the vascular system and connective tissues (see
Fonsatti et al., 2001, for a review). In this work, we
show for the ﬁrst time that endoglin is expressed in the
epidermis and skin appendages, such as hair follicles and
sweat glands. The presence of endoglin in normal
interfollicular epidermis is restricted to keratinocytes
of the basal, proliferative, layer, whereas none is
detected on suprabasal keratinocytes. This pattern of
expression is disrupted in human cutaneous hyperpro-
liferative lesions, such as seborrheic keratosis, and in
tumors, such as human basal and squamous cell
carcinomas and mouse DMBA/TPA-induced papillo-
mas, where aberrant endoglin expression in suprabasal
layers occurs.
To analyse the potential role of endoglin in tumor
formation and malignant progression, we used a skin
multistage carcinogenesis model in heterozygous C57Bl/
6 Engþ / mice. These mice develop normally, and
clinical signs of HHT were present in the 129/Ola strain,
but almost absent in the C57Bl/6 strain (Bourdeau et al.,
1999, 2001). None of the Engþ / C57Bl/6 mice used in
our experiments showed nosebleeds or telangiectases.
Our results show that a reduction of Endoglin gene
dosage has profound effects on skin neoplasia, affecting
both early and late stages of tumorigenesis. Decreased
endoglin expression suppresses benign tumor out-
growth, but accelerates malignant conversion and
development of highly aggressive poorly differentiated
carcinomas, a phenotype ﬁrst observed in transgenic
mice overexpressing TGF-b1 in the epidermis (Cui et al.,
1996). This study as well as those from other labora-
tories have led to postulation of a dual role for TGF-b1
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Figure 4 Rate of appearance of tumors in Engþ /þ () and Engþ /
(J) mice. The average number of tumors (over 2mm in diameter)
per mouse is plotted versus the number of weeks after initiation
with DMBA. In both experiments, reduction in the average tumor
number per mouse in Engþ / versus Engþ /þ mice is statistically
signiﬁcant when the tumor numbers reach the plateau. Thus, for
example, at weeks 22 and 23 in experiment 1 (P-values o0.05 and
o0.01, respectively, using a Student t-test) and at weeks 17 and 18
in experiment 2 (Po0.05 and P¼ 0.01, respectively)
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in carcinogenesis (Akhurst and Balmain, 1999; Massa-
gue´ et al., 2000; Derynck et al., 2001; Rich et al., 2001).
TGF-b1 acts as a suppressor of tumor formation, early
in carcinogenesis – by virtue of its well-established
antimitogenic function in epithelial cells (Roberts and
Sporn, 1990; Alexandrov and Moses, 1995). At later
stages, TGF-b1 stimulates malignant progression by
inducing an epithelial–mesenchymal transition toward
an invasive and metastatic phenotype (Caulı´n et al.,
1995; Cui et al., 1996; Oft et al., 1996; Frontelo et al.,
1998; Portella et al., 1998), likely in cooperation with
oncogenic Ras (Oft et al., 1996, 2002). These TGF-b
Figure 5 Histology of tumors induced in Engþ / mice. (a) Well-differentiated papilloma showing abundant keratin. (b) Squamous cell
carcinoma grades I–II. Note nests of tumor cells (tn) and keratin invading deep into the dermis (d); e, epidermis. (c) Detail of a well-
differentiated squamous cell carcinoma inﬁltrating muscle tissue (m). (d) Poorly differentiated carcinoma grades III–IV; t, tumor; s,
stroma. Original magniﬁcations:  100 (b),  200 (a, d),  400 (c)
Table 1 Evaluation of tumor yield and histological grade in Eng+/ with respect to Eng+/+ mice after DMBA/TPA skin carcinogenesisa
Cumulative number of tumors
Mouse line Number of animals with tumors Papilloma SCC I–II SCC III–IV Total
Eng+/+ 13/15 45 — — 45
Eng+/ 7/16 5 5 4 14
aAt the termination of the carcinogenesis experiment (25 weeks post DMBA in experiment 1 and 23 weeks post DMBA in experiment 2), all tumors
were enumerated and histologically typed. SCC, squamous cell carcinoma.
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effects occur within the tumor cells themselves and
require signaling through serine/threonine kinase recep-
tors (Oft et al., 1998; Portella et al., 1998). Considering
this mechanism of action of TGF-b1 our results strongly
suggest that the endoglin level on epithelial keratino-
cytes is critical for the mediation of TGF-b1 inhibitory
effect since the generation of benign tumors is inhibited
in Engþ / mice. However, transformation to a more
malignant phenotype is observed in these mice, suggest-
ing that normal levels of endoglin would inhibit the
effect of TGF-b1 on malignant progression.
It can be argued, however, that defects in neovascu-
larization could play an additional role in the phenotype
observed in our Engþ / mice, since endoglin is highly
expressed on the tumor-associated angiogenic vascular
endothelium (Burrows et al., 1995; Bodey et al., 1998;
Kumar et al., 1999; Li et al., 2001; Takahashi et al.,
2001). The importance of angiogenesis for the growth of
solid tumors is well recognized (Hanahan and Folkman,
1996). It has been shown that angiogenesis is a rate-
limiting step in the genesis of premalignant lesions such
as mouse skin papillomas (Bolontrade et al., 1998;
Larcher et al., 1998), decreased in Engþ / mice in this
study. Angiogenesis is also decisive for tumor progres-
sion, and halting angiogenesis inhibits development of
invasive carcinomas and restores the benign phenotype
of malignant keratinocytes (Skobe et al., 1997). There-
fore, it is unlikely that defective angiogenesis would
account for the dual phenotype exhibited by Engþ /
mice during carcinogenesis: decreased tumor formation
and accelerated malignant progression. Interestingly, a
recent report shows that decreased endoglin expression
in cultured human prostate cancer cells enhances cell
migration and invasion, while increased expression has
opposite effects (Liu et al., 2002). These ﬁndings suggest
that the level of endoglin expression can modulate
adhesion and motility in transformed epithelial cells,
and are in line with the results presented here that
reduced endoglin expression in keratinocytes favors
progression to invasive carcinomas.
A function for endoglin as an attenuator of TGF-b1
signaling is supported by our previous studies showing
that endoglin inhibits the TGF-b1 antiproliferative and
certain TGF-b1-dependent cellular responses (Lastres
et al., 1996; Letamendia et al., 1998a; Diez-Marques
et al., 2002). Although the molecular mechanism by
which endoglin modulates TGF-b responses remains to
be determined, a recent report suggests that by directly
Figure 6 Immunohistochemical detection of endoglin in tumors induced in Engþ /þ and Engþ / mice. (a) Engþ /þ normal skin. Note
positive staining in basal keratinocytes (arrows) and hair follicles (hf). (b) Normal skin distant from a papilloma induced in an Engþ /þ
mouse. Note that the epidermis is still slightly hyperplastic. (c) Engþ /þ papilloma. (d) Engþ / papilloma. Original magniﬁcations:
 200 (a, b, d),  400 (c)
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interacting with the signaling receptors types I and II,
endoglin regulates their phosphorylation status and
subsequently their signaling activity (Guerrero-Esteo
et al., 2002). TGF-b1 is an endogenous regulator of
epidermal homeostasis that is preferentially expressed in
suprabasal layers, where it is thought to block prolifera-
tion of differentiating keratinocytes (Akhurst et al.,
1988; Fowlis et al., 1992; Patamalai et al., 1994).
Interestingly, endoglin is synthesized in basal prolifera-
tive keratinocytes, the appropriate cell type to counter-
act the negative regulation of growth exerted by this
factor. Anomalous endoglin expression in suprabasal
keratinocytes, as observed in papillomas and carcino-
mas and other cutaneous hyperplastic disorders, is likely
associated with expansion of the proliferative keratino-
cyte compartment in these lesions (Yuspa, 1994). Thus,
we postulate that the relative levels of endoglin and
TGF-b1 production can mediate the strength of the
cellular responses to the growth factor, pointing to
endoglin as a potential new target to explore therapeutic
strategies to control TGF-b-mediated tumor progres-
sion.
Materials and methods
Cell lines and culture
The origin of the mouse epidermal cell lines: Pam212, PB,
PDV, HaCa4, Car C, and Car B used in this work has been
described (Yuspa et al., 1986; Dı´az-Guerra et al., 1992).
NIH3T3 mouse ﬁbroblast cell line was obtained from the
American Type Culture Collection (Rockville, MD, USA).
Cells were grown in Ham’s F12 medium supplemented with
amino acids and vitamins (Pam212, PB, HaCa4, PDV) or
Dulbecco’s modiﬁed Eagle’s medium (NIH3T3, Car C, and
Car B), with 10% fetal calf serum (Gibco Invitrogen Corp.,
Barcelona, Spain) and antibiotics (2.5 mg/ml amphotericin B,
100mg/ml ampicillin, and 32mg/ml gentamicin; Sigma-Aldrich,
Madrid, Spain). Cultures were maintained on plastic at 371C
in a 5% CO2-humidiﬁed atmosphere.
Endoglin heterozygous mice
Endoglin heterozygous (Engþ /) mice were generated by
homologous recombination using embryonic stem cells of
129/Ola (129) origin and by backcrossing onto the C57BL/6
(B6) background, as previously described (Bourdeau et al.,
1999). B6-Engþ / mice of N4 generation were used in the
present studies, as well as their B6-Engþ /þ littermate controls.
Genotypes were determined by PCR analysis of tail DNA
isolated using two sets of primers amplifying a 470 bp product
in the mutated allele, and a 300 bp product in the wild-type
allele (Bourdeau et al., 1999). Mice were bred and kept in
ventilated rooms, in a germ-free facility, under controlled
conditions of light, temperature, humidity, food, and water
(Rodriguez-Pen˜a et al., 2002). Engþ / mice were fertile,
showing a normal ratio of male to female progeny,
had a normal lifespan, and did not show any visible vascular
abnormality. In all procedures, mice were treated in
accordance with the international and national institution’s
guidelines for the care and use of laboratory animals:
Conseil de l’Europe (published in the Ofﬁcial Daily
No. L358/1-358/6, 18th December 1986), Spanish
Government (published in Boletı´n Oﬁcial del Estado No. 67,
pp. 8509–8512, 18th March 1988, and Boletı´n Oﬁcial del
Estado No. 256, pp. 31349–31362, 28th October 1990), and the
Guide for the Care and Use of Laboratory Animals, published
by the US National Institutes of Health (NIH Publication
No. 85–23).
Chemical carcinogenesis
Tumors were induced on the shaved dorsal skin of 10-week-old
mice by a single topical application of 32 mg of DMBA in
200 ml acetone, followed by treatment twice a week
with 12.5mg. of TPA in 200 ml acetone (104m). The number
of tumors (42mm in diameter) on each mouse was recorded
every week. Mice were anesthetized and killed at the end
of the experiments, and tumors were ﬁxed in formalin and
embedded in parafﬁn. The tumors were histologically typed by
hematoxylin and eosin staining of parafﬁn sections. Although
the pure B6 genetic background is refractory to DMBA/TPA
carcinogenesis (Reiners et al., 1984), the N4 generation of
129B6 mice used in this study yielded four to ﬁve tumors per
mouse.
Antibodies and immunohistochemical analysis
The human endoglin-speciﬁc mAb SN6h (Dako Diagnosticos,
Barcelona, Spain) was used for staining formalin-ﬁxed tissues.
The mAbMJ7/18 recognizes mouse endoglin (Ge and Butcher,
1994), and was purchased from BD Biosciences (Heidelberg,
Germany). Immunohistochemical detection of endoglin was
performed in deparafﬁnized human and mouse tissue sections
by the Envision plus peroxidase method (Dako A/S, Glostrup,
Denmark), as previously reported (Velasco et al., 2001). The
reaction product was developed with diaminobenzidine tetra-
hydrochloride and H2O2. The sections were dehydrated in
graded ethanols, cleared in xylene, and mounted in Permount
after counterstaining with hematoxylin.
Northern, RT—PCR, and Western blot analyses
Northern blot hybridization experiments were performed with
total RNA extracted from the cell lines by the guanidinium
thiocyanate procedure. RNA samples (25 mg) were fractio-
nated on 1% agarose–formaldehyde gels and transferred to
Nylon membranes (Schleicher and Schuell, Dassel, Germany).
The probe for endoglin mRNA detection was a fragment of
1040 bp generated by RT–PCR from mouse keratinocytes (PB
cell line), using oligonucleotides ﬂanking the coding sequence
corresponding to the extracellular domain: 50-
GTGTGTCTGGTCACAAGGAGGC-30 (nucleotides 1001–
1022) and 50-GGACAAGGTGCTAGGGCGCAGA-30 (nu-
cleotides 2019–2040). PCR conditions were 35 cycles: 951C for
1min, 631C for 1min 30 s, 721C for 1min. For RT–PCR
analysis, total RNA samples were incubated with the Moloney
murine leukemia virus reverse transcriptase (Promega Cor-
poration, Madison, WI, USA) and the generated cDNAs were
used for PCR ampliﬁcation as described above. PCR products
were fractionated in 1% agarose–ethidium bromide gels. The
1040-bp band was isolated using a gel extraction kit
(QIAquick; QiagenGmbH, Hilden, Germany) and sequenced
in an ABI PRISM 377 machine (PE Applied Biosystems,
Foster City, CA, USA).
For detection of endoglin in Western blots, cells were
lysed at 41C in buffer RIPA and a cocktail of proteinase
inhibitors as previously described (Frontelo et al., 1998).
Aliquots of total cell lysates containing equivalent amounts of
protein (30 mg) were separated by 7.5% SDS–PAGE
under reducing conditions and electrotransferred to Immobi-
lon P membranes (Millipore Corporation, Bedford,
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MA, USA) for immunodetection with the rat anti-mouse
endoglin mAb MJ7/18 or preimmune rat IgG. As secondary
Ab, goat anti-rat IgG coupled to horseradish peroxidase
(Pierce, Perbio Science, Bonn, Germany) was used.
Filters were reblotted with the anti-a-tubulin mAb DM1A
(Sigma Aldrich). The peroxidase activity was developed
using an enhanced chemiluminescence kit (Amersham
Biosciences).
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